Cilostazol attenuates ventricular arrhythmia induction and improves defibrillation efficacy in swine

Canadian Journal of Physiology and Pharmacology

Volumn 88, Issue 4, 2010, Pages 422-428

  Kanlop, Natnicha ^a   Shinlapawittayatorn, Krekwit ^a   Sungnoon, Rattapong ^a   Weerateerangkul, Punate ^a   Chattipakorn, Siriporn ^a   Chattipakorn, Nipon ^a,b  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b Cardiac Electrophysiology Unit   (Thailand)

Author keywords

Arrhythmia inducibility; Cilostazol; Defibrillation threshold; Phosphodiesterase 3; Upper limit of vulnerability; Ventricular fibrillation threshold

Indexed keywords

CILOSTAZOL; PHOSPHODIESTERASE III INHIBITOR; ANTIARRHYTHMIC AGENT; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRUGADA SYNDROME; CONTROLLED STUDY; DEFIBRILLATION; DEFIBRILLATION THRESHOLD; DRUG MECHANISM; FEMALE; HEART ELECTROPHYSIOLOGY; HEART FUNCTION TEST; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; MALE; NONHUMAN; PRIORITY JOURNAL; SWINE; UPPER LIMIT OF VULNERABILITY; ANIMAL; ARRHYTHMIAS, CARDIAC; CARDIOVERSION; DRUG EFFECTS; HEART MUSCLE CONDUCTION SYSTEM; RANDOMIZATION; VENTRICULAR FIBRILLATION;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; ELECTRIC COUNTERSHOCK; FEMALE; HEART CONDUCTION SYSTEM; MALE; RANDOM ALLOCATION; SWINE; TETRAZOLES; VENTRICULAR FIBRILLATION;

EID: 77952026026     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y09-127     Document Type: Article

References (32)

1. Atarashi, H., Endoh, Y., Saitoh, H., Kishida, H., and Hayakawa, H. 1998. Chronotropic effects of cilostazol, a new antithrombotic agent, in patients with bradyarrhythmias. J. Cardiovasc. Pharmacol. 31(4): 534-539. doi:10.1097/00005344-199804000-00010. PMID:9554801.
2. Chattipakorn, N., Fotuhi, P.C., and Ideker, R.E. 2000a. Prediction of defibrillation outcome by epicardial activation patterns following shocks near the defibrillation threshold. J. Cardiovasc. Electrophysiol. 11(9): 1014-1021. doi:10.1111/j.1540-8167.2000.tb00174.x. PMID:11021472.
3. Chattipakorn, N., Fotuhi, P.C., Zheng, X., and Ideker, R.E. 2000b. Left ventricular apex ablation decreases the upper limit of vulnerability. Circulation, 101(21): 2458-2460. PMID:10831517. (Pubitemid 30366247)
4. Chattipakorn, N., Rogers, J.M., and Ideker, R.E. 2000c. Influence of postshock epicardial activation patterns on initiation of ventricular fibrillation by upper limit of vulnerability shocks. Circulation, 101(11): 1329-1336. PMID:10725295.
5. Chattipakorn, N., Shinlapawittayatorn, K., Sungnoon, R., and Chattipakorn, S.C. 2006. Effects of n-3 polyunsaturated fatty acid on upper limit of vulnerability shocks. Int. J. Cardiol. 107(3): 299-302. doi:10.1016/j.ijcard.2005.03.032. PMID:16503251.
6. Chen, P.S., Shibata, N., Dixon, E.G., Martin, R.O., and Ideker, R.E. 1986. Comparison of the defibrillation threshold and the upper limit of ventricular vulnerability. Circulation, 73(5): 1022-1028. PMID:3698224. (Pubitemid 16102193)
7. Compos, A.T., Malkin, R.A., and Ideker, R.E. 1997. An up-down Bayesian, defibrillation efficacy estimator. Pacing Clin. Electrophysiol. 20(5 Pt 1): 1292-1300. doi:10.1111/j.1540-8159.1997.tb06782.x. PMID:9170129.
8. Cone, J., Wang, S., Tandon, N., Fong, M., Sun, B., Sakurai, K., et al. 1999. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J. Cardiovasc. Pharmacol. 34(4): 497-504. doi:10.1097/00005344-199910000-00004. PMID:10511123.
9. Dawson, D.L., Cutler, B.S., Meissner, M.H., and Strandness, D.E., Jr. 1998. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation, 98(7): 678-686. PMID:9715861.
10. Feldman, A.M., Bristow, M.R., Parmley, W.W., Carson, P.E., Pepine, C.J., Gilbert, E.M., et al.Vesnarinone Study Group. 1993. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N. Engl. J. Med. 329(3): 149-155. doi:10.1056/NEJM199307153290301. PMID:8515787.
11. + channels in rabbit hearts. J. Pharmacol. Exp. Ther. 326(1): 100-104. doi:10.1124/jpet.108. 136218. PMID:18381926.
12. Goldstein, R.A., Geraci, S.A., Gray, E.L., Rinkenberger, R.L., Dougherty, A.H., and Naccarelli, G.V. 1986. Electrophysiologic effects of milrinone in patients with congestive heart failure. Am. J. Cardiol. 57(8): 624-628. doi:10.1016/0002-9149(86) 90847-7. PMID:3953448.
13. Green, U.B., Garg, A., Al-Kandari, F., Ungab, G., Tone, L., and Feld, G.K. 2003. Successful implantation of cardiac defibrillators without induction of ventricular fibrillation using upper limit of vulnerability testing. J. Interv. Card. Electrophysiol. 8(1): 71-75. doi:10.1023/A:1022304417889. PMID:12652181.
14. Hakaim, A.G., Cunningham, L., White, J.L., and Hoover, K. 1999. Selective type III phosphodiesterase inhibition prevents elevated compartment pressure after ischemia/reperfusion injury. J. Trauma, 46(5): 869-872. doi:10.1097/00005373-199905000-00016. PMID:10338405.
15. Hambleton, R., Krall, J., Tikishvili, E., Honeggar, M., Ahmad, F., Manganiello, V.C., and Movsesian, M.A. 2005. Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium. J. Biol. Chem. 280(47): 39168-39174. doi:10.1074/jbc.M506760200. PMID:16172121.
16. Kanlop, N., Shinlapawittayatorn, K., Sungnoon, R., Chattipakorn, S., Lailerd, N., and Chattipakorn, N. 2008. Sildenafil citrate on the inducibility of ventricular fibrillation and upper limit of vulnerability in swine. Med. Sci. Monit. 14(10): BR205-BR209. PMID:18830184.
17. Kodama-Takahashi, K., Kurata, A., Ohshima, K., Yamamoto, K., Uemura, S., Watanabe, S., and Iwata, T. 2003. Effect of cilostazol on the ventricular escape rate and neurohumoral factors in patients with third-degree atrioventricular block. Chest, 123(4): 1161-1169. doi:10.1378/chest.123.4.1161. PMID:12684307.
18. Lakkireddy, D., Wallick, D., Ryschon, K., Chung, M.K., Butany, J., Martin, D., et al. 2006. Effects of cocaine intoxication on the threshold for stun gun induction of ventricular fibrillation. J. Am. Coll. Cardiol. 48(4): 805-811. doi:10.1016/j.jacc.2006.03.055. PMID:16904553.
19. Madias, J.E. 2003. Cilostazol: an "intermittent claudication" remedy for the management of third-degree AV block. Chest, 123(4): 979-982. doi:10.1378/chest.123.4.979. PMID:12684279.
20. Mair, J., Hammerer-Lercher, A., and Puschendorf, B. 2001. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin. Chem. Lab. Med. 39(7): 571-588. doi:10.1515/CCLM.2001.093. PMID:11522102.
21. Malkin, R.A., and Hoffmeister, B.K. 2000. Hemodynamic collapse, geometry, and the rapidly paced upper limit of ventricular vulnerability to fibrillation by T-wave stimulation. J. Electrocardiol. 33(3): 279-286. doi:10.1054/jelc.2000. 7663. PMID:10954381.
22. Miles, W.M., Heger, J.J., Minardo, J.D., Klein, L.S., Prystowsky, E.N., and Zipes, D.P. 1989. The electrophysiologic effects of enoximone in patients with preexisting ventricular tachyarrhythmias. Am. Heart J. 117(1): 112-121. doi:10.1016/0002-8703(89)90664-9. PMID:2521415.
23. Naccarelli, G.V., Gray, E.L., Dougherty, A.H., Hanna, J.E., and Goldstein, R.A. 1984. Amrinone: acute electrophysiologic and hemodynamic effects in patients with congestive heart failure. Am. J. Cardiol. 54(6): 600-604. doi:10.1016/0002-9149(84)90257-1. PMID:6475780.
24. Olfert, O.D., Cross, B.M., and McWilliam, A.A. (Editors). 1993. Guide to the care and use of experimental animals. 2nd ed. Canadian Council on Animal Care, Ottawa, Canada.
25. Packer, M., Carver, J.R., Rodeheffer, R.J., Ivanhoe, R.J., DiBianco, R., Zeldis, S.M., et al.; The PROMISE Study Research Group. 1991. Effect of oral milrinone on mortality in severe chronic heart failure. N. Engl. J. Med. 325(21): 1468-1475. PMID: 1944425.
26. Rodríguez, B., and Trayanova, N. 2003. Upper limit of vulnerability in a defibrillation model of the rabbit ventricles. J. Electrocardiol. 36(Suppl): 51-56. doi:10.1016/j.jelectrocard.2003.09.066. PMID:14716592.
27. Saitoh, S., Saito, T., Otake, A., Owada, T., Mitsugi, M., Hashimoto, H., and Maruyama, Y. 1993. Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator. Arterioscler. Thromb. 13(4): 563-570. PMID: 8385480.
28. Shinlapawittayatorn, K., Sungnoon, R., Chattipakorn, S., and Chattipakorn, N. 2006. Effects of sildenafil citrate on defibrillation efficacy. J. Cardiovasc. Electrophysiol. 17(3): 292-295. doi:10.1111/j.1540-8167.2006. 00348.x. PMID:16643403.
29. Sungnoon, R., Kanlop, N., Chattipakorn, S.C., Tawan, R., and Chattipakorn, N. 2008. Effects of garlic on the induction of ventricular fibrillation. Nutrition, 24(7-8): 711-716. doi:10.1016/j.nut.2008.03.003. PMID:18456459.
30. Swerdlow, C., Shivkumar, K., and Zhang, J. 2003. Determination of the upper limit of vulnerability using implantable cardioverter-defibrillator electrograms. Circulation, 107(24): 3028-3033. doi:10.1161/01.CIR.0000074220. 19414.18. PMID:12810611.
31. Tsuchiya, T., Ashikaga, K., Honda, T., and Arita, M. 2002. Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J. Cardiovasc. Electrophysiol. 13(7): 698-701. doi:10.1046/j.1540-8167.2002.00698.x. PMID:12139296.
32. 2+ current in rat ventricular myocytes. Br. J. Pharmacol. 127(1): 65-74. doi:10.1038/sj.bjp.0702506. PMID:10369457.